MANNHEIM, Germany, April 23, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced an abstract on the phase 2 LuminICE-203 study of its innate cell engager (ICE®) acimtamig in combination with AlloNK® (AB-101) has been accepted for an oral presentation at the Annual Meeting of the American Society for Clinical Oncology (ASCO) taking place May 30 – June 3, 2025 in Chicago, Illinois. In addition, two abstracts on AFM24 in combination with atezolizumab in non-small cell lung cancer (NSCLC) have been accepted as poster presentations.
Details of the acimtamig oral presentation and AFM24 poster presentations are as follows:
| Abstract Title & Number | Date & Time | Session Type & Title |
| Results from the completed dose-finding part of a phase 2 study of the innate cell engager acimtamig (AFM13) in combination with AlloNK (AB-101) in relapsed or refractory classical Hodgkin lymphoma (LuminICE-203) Abstract Number for Publication: 7008 | May 30, 2025 2:45 PM-5:45 PM CDT | Oral Abstract Session – Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia |
| Bispecific innate cell engager (ICE) AFM24 in combination with atezolizumab in patients with advanced/metastatic EGFR-expressing non-small cell lung cancer (NSCLC) without driver mutations: Initial results from a phase 2a study Abstract Number for Publication: 2609 | June 2, 2025 1:30 PM-4:30 PM CDT | Poster Session – Developmental Therapeutics—Immunotherapy Poster Board: 256 |
| Combination of bispecific innate cell engager (ICE) AFM24 with atezolizumab in patients with advanced/metastatic non-small cell lung cancer (NSCLC) with EGFR kinase domain mutations (EGFRmut): Initial results from a phase 2a study Abstract Number for Publication: 2610 | June 2, 2025 1:30 PM-4:30 PM CDT | Poster Session – Developmental Therapeutics—Immunotherapy Poster Board: 257 |
The full abstracts will be published online on May 22, 2025.
More details about the programs for the 2025 ASCO Annual Meeting are available online at Attend | ASCO Annual Meeting.
About Affimed N.V.
Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The Company’s innate cell engagers (ICE®) enable a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors. ICE® are generated on the Company’s proprietary ROCK® platform which predictably generates customized molecules that leverage the power of innate immune cells to destroy tumor cells. A number of ICE® molecules are in clinical development, being studied as mono- or combination therapy. Headquartered in Mannheim, Germany, Affimed is led by an experienced team of biotechnology and pharmaceutical leaders united by the bold vision to stop cancer from ever derailing patients’ lives. For more about the Company’s people, pipeline and partners, please visit: www.affimed.com.
Investor Relations Contact
Alexander Fudukidis
Director, Investor Relations
E-Mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
Tel.: +1 (917) 436-8102
Media Contact
Mary Beth Sandin
Vice President, Marketing and Communications
E-Mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$0.77 |
| Daily Change: | 0.03 4.19 |
| Daily Volume: | 93,948 |
| Market Cap: | US$12.620M |
December 17, 2024 December 09, 2024 December 09, 2024 | |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
